plasma-derived human coagulation factor VIII / China Biologic Products - LARVOL DELTA

China Biologic Products Inc (CBPO) Q3 2020 Earnings Call Transcript (The Motley Fool) - "For our new product coagulation factor IX for which we received a certificate of approval for manufacturing in late July, we have begun manufacturing and are waiting for the batch approval for the first batch of this product. We're also applying for the inclusion of this product in the National Reimbursement List to improve accessibility to hospitals and customers....For plasma products, total sales in third quarter 2020 increased by 0.8% in US dollar terms...Revenue from other plasma products increased by 15.2% in US dollar terms, or 13.9% in RMB terms, in the third quarter of 2020..."

Non-US regulatory • Reimbursement • Sales • Hemophilia